CA2091360C - Mometasone furoate monohydrate, process for making same and pharmaceutical compositions - Google Patents

Mometasone furoate monohydrate, process for making same and pharmaceutical compositions

Info

Publication number
CA2091360C
CA2091360C CA002091360A CA2091360A CA2091360C CA 2091360 C CA2091360 C CA 2091360C CA 002091360 A CA002091360 A CA 002091360A CA 2091360 A CA2091360 A CA 2091360A CA 2091360 C CA2091360 C CA 2091360C
Authority
CA
Canada
Prior art keywords
alpha
monohydrate
furoate
mometasone furoate
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002091360A
Other languages
English (en)
French (fr)
Other versions
CA2091360A1 (en
Inventor
Pui-Ho Yuen
Charles Eckhart
Teresa Etlinger
Nancy Levine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24320279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2091360(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2091360A1 publication Critical patent/CA2091360A1/en
Application granted granted Critical
Publication of CA2091360C publication Critical patent/CA2091360C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002091360A 1990-09-10 1991-09-06 Mometasone furoate monohydrate, process for making same and pharmaceutical compositions Expired - Lifetime CA2091360C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58023990A 1990-09-10 1990-09-10
US580,239 1990-09-10

Publications (2)

Publication Number Publication Date
CA2091360A1 CA2091360A1 (en) 1992-03-11
CA2091360C true CA2091360C (en) 1997-04-08

Family

ID=24320279

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002091360A Expired - Lifetime CA2091360C (en) 1990-09-10 1991-09-06 Mometasone furoate monohydrate, process for making same and pharmaceutical compositions

Country Status (35)

Country Link
US (1) US6180781B1 (OSRAM)
EP (1) EP0548114B1 (OSRAM)
JP (1) JPH0725789B2 (OSRAM)
KR (1) KR960013445B1 (OSRAM)
CN (1) CN1030920C (OSRAM)
AT (1) ATE113604T1 (OSRAM)
AU (1) AU663471B2 (OSRAM)
BG (1) BG60755B2 (OSRAM)
CA (1) CA2091360C (OSRAM)
CZ (1) CZ281318B6 (OSRAM)
DE (2) DE69104991T2 (OSRAM)
DK (1) DK0548114T5 (OSRAM)
EE (1) EE02962B1 (OSRAM)
ES (1) ES2065701T3 (OSRAM)
FI (1) FI111078B (OSRAM)
HK (1) HK185996A (OSRAM)
HR (1) HRP920383B1 (OSRAM)
HU (1) HU213401B (OSRAM)
IE (1) IE67056B1 (OSRAM)
IL (1) IL99437A (OSRAM)
LU (1) LU90366I2 (OSRAM)
MX (2) MX9203396A (OSRAM)
MY (1) MY106644A (OSRAM)
NL (1) NL980012I2 (OSRAM)
NO (1) NO300548B1 (OSRAM)
NZ (1) NZ239711A (OSRAM)
OA (1) OA09772A (OSRAM)
PH (1) PH30443A (OSRAM)
PL (1) PL165803B1 (OSRAM)
PT (1) PT98905B (OSRAM)
SI (1) SI9111497A (OSRAM)
TW (2) TW229208B (OSRAM)
WO (1) WO1992004365A1 (OSRAM)
YU (1) YU48666B (OSRAM)
ZA (1) ZA917148B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203396A (es) * 1990-09-10 1992-07-31 Schering Corp Monohidrato de furoato de mometasona, proceso para producirlo y composiciones farmaceuticas.
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
CN1059476C (zh) * 1996-08-21 2000-12-13 邓维鹏 金黄色铝合金硒盐电解着色方法
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
JP3676674B2 (ja) * 1997-10-09 2005-07-27 シェーリング コーポレイション 噴霧のためのモメタゾンフロエート懸濁液
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
CN1250563C (zh) 1999-05-04 2006-04-12 斯特拉坎有限公司 雄激素糖苷及其产生雄性征的活性
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
BRPI0617674A2 (pt) 2005-10-19 2011-08-02 Ranbaxy Lab Ltd composições farmacêuticas e seus usos
WO2007045980A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
HRP20120361T1 (hr) 2007-03-14 2012-05-31 Ranbaxy Laboratories Limited DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE
WO2008111009A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SI2435024T1 (sl) 2009-05-29 2016-10-28 Pearl Therapeutics, Inc. Zmesi za respiratorni vnos aktivnih sredstev in s tem povezane metode in sistemi
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
EP2968152B2 (en) 2013-03-15 2022-06-22 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法
CN107260671B (zh) * 2016-04-08 2021-03-26 天津金耀集团有限公司 一种糠酸莫米松混悬鼻喷剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0057401B1 (en) * 1981-02-02 1984-08-01 Schering Corporation Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4783444A (en) 1984-09-17 1988-11-08 Schering Corporation Antiglaucoma compositions and methods
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
MX9203396A (es) * 1990-09-10 1992-07-31 Schering Corp Monohidrato de furoato de mometasona, proceso para producirlo y composiciones farmaceuticas.

Also Published As

Publication number Publication date
US6180781B1 (en) 2001-01-30
TW272195B (OSRAM) 1996-03-11
HRP920383B1 (en) 2000-04-30
KR960013445B1 (ko) 1996-10-05
FI931031A0 (fi) 1993-03-09
TW229208B (OSRAM) 1994-09-01
JPH05506667A (ja) 1993-09-30
LU90366I2 (fr) 1999-05-05
MX9203396A (es) 1992-07-31
PH30443A (en) 1997-05-09
EP0548114B1 (en) 1994-11-02
AU663471B2 (en) 1995-10-12
CN1030920C (zh) 1996-02-07
HU9300685D0 (en) 1993-06-28
NZ239711A (en) 1992-09-25
DE19875032I2 (de) 2007-04-19
HK185996A (en) 1996-10-11
DE69104991T2 (de) 1995-04-20
MY106644A (en) 1995-07-31
ATE113604T1 (de) 1994-11-15
SI9111497A (sl) 1998-04-30
PL165803B1 (pl) 1995-02-28
CZ281318B6 (cs) 1996-08-14
YU149791A (sh) 1994-01-20
MX9100990A (es) 1992-05-04
DK0548114T5 (da) 1995-01-30
IL99437A0 (en) 1992-08-18
ES2065701T3 (es) 1995-02-16
JPH0725789B2 (ja) 1995-03-22
WO1992004365A1 (en) 1992-03-19
OA09772A (en) 1993-11-30
YU48666B (sh) 1999-06-15
HUT64361A (en) 1993-12-28
EP0548114A1 (en) 1993-06-30
CZ38393A3 (en) 1994-01-19
FI111078B (fi) 2003-05-30
DE69104991D1 (de) 1994-12-08
EE02962B1 (et) 1997-02-17
CA2091360A1 (en) 1992-03-11
BG60755B2 (bg) 1996-02-29
PT98905B (pt) 1998-08-31
NO300548B1 (no) 1997-06-16
NL980012I1 (nl) 1998-05-06
IE67056B1 (en) 1996-02-21
ZA917148B (en) 1992-08-26
HU213401B (en) 1997-06-30
NO930693D0 (no) 1993-02-26
AU8497491A (en) 1992-03-30
IL99437A (en) 1995-05-29
HRP920383A2 (en) 1998-06-30
NL980012I2 (nl) 2004-11-01
PT98905A (pt) 1992-09-30
FI931031L (fi) 1993-03-09
CN1059911A (zh) 1992-04-01
IE913155A1 (en) 1992-03-11
NO930693L (no) 1993-02-26

Similar Documents

Publication Publication Date Title
CA2091360C (en) Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US6127353A (en) Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
JPH0714880B2 (ja) エアゾル用に適するよう物理的に修正されたベクロメタソンジプロピオネ−ト
JP2016517410A (ja) トレプロスチニルの固体形態
TW201736383A (zh) 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形
JP2024028460A (ja) 化合物の結晶形態及び化合物の結晶形態を生成する方法
KR102657147B1 (ko) 빌라스틴의 결정형 및 그의 제조 방법
NO163899B (no) Fremgangsm te for fremstilling av diisopropyletersov beclometason-17,21-dipropionat.
TWI672302B (zh) Bcl-2抑制劑之新結晶型、其製備方法及含其之醫藥組合物
KR102210848B1 (ko) 3-포르밀리파마이신 sv 및 3-포르밀리파마이신 s의 3-(4-신나밀-1-피페라지닐) 아미노 유도체를 함유하는 제약 제제 및 그의 제조 방법
EP1651661B1 (en) Process for the preparation of finasteride form i
US7208485B2 (en) Crystalline forms of halobetasol propionate
CN120247881A (zh) 一种瑞司美替罗新晶型及其制备方法
GB2410948A (en) Novel phosphoric acid salt of rosiglitazone
US20240199642A1 (en) Method for obtaining rifapentine with a new crystalline form
WO2025201325A1 (zh) 4-[3-(环丙基甲氧基)-4-(二氟甲氧基)苯乙基]吡啶-2(1h)-酮的固体形式及其制备方法
CN116239527A (zh) 一种米力农-柠檬酸一水共晶体
GB2421240A (en) Phosphoric acid salt of rosiglitazone
JPH0129199B2 (OSRAM)
WO2004083230A1 (en) Novel crystalline forms of finasteride

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry